Wire · operational-macro
aTyr Pharma Reaches FDA Protocol Agreement for Efzofitimod Phase 3 Trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 September 2026 · Fusion42 review
aTyr Pharma has reached an agreement with the FDA on the protocol for a Phase 3 trial of Efzofitimod in treating pulmonary sarcoidosis with restrictive lung disease, enabling planned filings in the U.S. and Europe and signalling regulatory alignment for a pivotal study.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 24 Sep 2026 and 25 Sep 2026.
◆ ◆ The Wire takeaway
Your biotech firm now has a clearer path to launch drugs for pulmonary sarcoidosis as FDA protocol agreement reduces trial delays. Track aTyr Pharma's IND and EU CTA filings this quarter to spot trial start momentum and regulatory risk.
◆ Coverage
2 sources · first reported 24 Sep 2026 · latest 25 Sep 2026
◆ Related on Wire
◆ Topics